INS and type 1 diabetes mellitus: The mounting evidence strongly supports incorporating GLP-1 RAs as adjunct therapies to insulin in adolescents with T1D offering benefits such as improved glycemic outcomes, weight reduction, and enhanced cardiovascular and renal health.